Ana Maria Corregidor, M.D.
Dr. Corregidor joins us after completing her Transplant/ Hepatology Fellowship at the MAYO Clinic in Jacksonville. In addition to her special training in Liver diseases, Ana completed a fellowship in Gastroenterology at the University of Florida. She has a special interest in pre and post liver transplant evaluation and management. Dr. Corregidor is the Medical Director of Borland-Groover Clinic’s Liver Center, and is active in several clinical trials investigating new drugs in the treatment of Hepatitis C and B, and other liver diseases. In addition, Dr. Corregidor performs colonoscopy and upper endoscopy.
Office locations
Practicing since
1991
Certifications
- Board Certified - Transplant and Hepatology, 2010
- Board Certified - Gastroenterology, 2004
- Board Certified - Internal Medicine, 1998
- ECFMG, 1995
- USMLE: (Step I, II, III), 1993 - 1997
National Provider Identifier
1306842810
Licensure
Florida
Professional Clinical Positions
| 2004 - Present | Director of Hepatology - Liver Clinic, Borland-Groover Clinic, P.A. | Jacksonville, Florida |
| 2008 - 2011 | Chief of Gastroenterology, St. Lukes Hospital | Jacksonville, Florida |
| 2002 – 2004 | Ambulatory Care Physician, Outpatient Clinics | Madrid, Spain |
| 1991 – 1992 | Ambulatory Care Physician, Outpatient Clinics | Madrid, Spain |
Medical Education
| 1985 – 1991 | Doctor of Medicine | Universidad Comlutense | Madrid, Spain |
Postgraduate Education
| 2001 – 2002 | Fellowship, Hepatology and Liver Transplantation | Mayo Clinic Jacksonville | Jacksonville, Florida |
| 2001 – 1998 | Fellowship, Gastroenterology | University of Florida, Shands | Jacksonville, Florida |
| 1998 – 1995 | Internship and Residency, Internal Medicine | St. Lukes Hospital, University of Columbia | St. Louis, Missouri |
Professional Associations
- AASLD – American Association for the Study of Liver Diseases
- DCMS – Duval County Medical Society
- Speaker Bureau for Schering Company
- A Phase 2 Study of Telaprevir(VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With A Prior Course of Interferon-Based Therapy - Sub Investigator
- A Roll Over Protcol of Telaprevir (VX-950)) In Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106 Who Do Not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response. - Sub Investigator
- A Phase III Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®),and Ribavirin (Copegus®) in Treatment- Naïve Subjects With Genotype 1 Chronic Hepatitis C. - Sub Investigator
- A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for The Induction of Remission In Subjects Experiencing Treatment-Refactory Moderate- to- Severe Crohn’s Disease. - Sub Investigator
- A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment – Refactory Moderate- to Severe Crohn’s Disease. - Sub Investigator
- A Randomized, Open Label, MulticenterStudy Examining the Effects of 24 Verses 48 Weeks of Combination Therapy With PEGASYS (Peginterferon alfa-2a-40 KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who Do Not Achieve A Rapid Viral Response. - Principal Investigator
- A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety,Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults with Non- Alcoholic Steatohepatitis (NASH) - Principal Investigator
- A Phase 3b, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects with Chronic Hepatitis B who are Resistant to Lamivudine - Principal Investigator
- Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Eficacy (as measured by Sustained Virological Response) and Safety of 360 Induction Dosing of Pegasys® In Combination with Higher Copegus® Doses in Treatment- naïve Patients with Chronic Hepatitis C Genotype I Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg. - Principal Investigator
- An open label trial of daily Interferon induction follow by combination ribavirin and daily high dose Interferon in HCV patients, A. Corregidor, J. Li, P. Ricci, L. Cubbedge, C.G. Bruno, L.R. Lambiase UFHSC., Jacksonville, Florida
- Effect of alcohol intake on clinical, virological and pathological aspects in patients with Hepatitis C., A. Corregidor, C. Monteiro, L.R. Lambiase, L. Cubbedge, C. Fang, J. Munoz, J. Li, UFHSC., Jacksonville, Florida
- Association of Liver Steatosis and Chronic Heaptitis C,. J. Li, A. Corregidor, C. Monteiro, L. Cubbedge, C. Fang, J. Munoz, L.R. Lambiase FHSC., Jacksonville, Florida